$17.27
2.86%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US1523091007
Symbol
CNTA

Centessa Pharmaceuticals plc - ADR Stock price

$17.27
+1.19 7.40% 1M
+2.23 14.83% 6M
+0.52 3.10% YTD
+3.77 27.93% 1Y
+12.56 266.67% 3Y
-4.48 20.60% 5Y
-4.48 20.60% 10Y
-4.48 20.60% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.48 2.86%
ISIN
US1523091007
Symbol
CNTA
Industry

Key metrics

Basic
Market capitalization
$2.2b
Enterprise Value
$2.1b
Net debt
positive
Cash
$250.7m
Shares outstanding
133.9m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
149.9 | 147.0
EV/Sales
140.5 | 137.7
EV/FCF
negative
P/B
6.5
Financial Health
Equity Ratio
69.6%
Return on Equity
-58.7%
ROCE
-51.9%
ROIC
-103.7%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$15.0m | $15.3m
EBITDA
$-239.2m | $-193.9m
EBIT
$-240.1m | $-188.4m
Net Income
$-230.8m | $-188.8m
Free Cash Flow
$-143.9m
Growth (TTM | estimate)
Revenue
119.0% | -
EBITDA
-54.8% | 3.1%
EBIT
-54.4% | 6.3%
Net Income
-46.5% | 19.9%
Free Cash Flow
1.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,594.7% | -1,267.4%
EBIT
-1,600.7%
Net
-1,538.7% | -1,234.0%
Free Cash Flow
-959.4%
More
EPS
$-1.7
FCF per Share
$-1.1
Short interest
4.1%
Employees
98
Rev per Employee
$0.0
Show more

Is Centessa Pharmaceuticals plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Centessa Pharmaceuticals plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Centessa Pharmaceuticals plc - ADR forecast:

Buy
95%
Hold
5%

Financial data from Centessa Pharmaceuticals plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
15 15
119% 119%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 51 51
4% 4%
340%
- Research and Development Expense 171 171
51% 51%
1,140%
-239 -239
55% 55%
-1,595%
- Depreciation and Amortization 0.91 0.91
5% 5%
6%
EBIT (Operating Income) EBIT -240 -240
54% 54%
-1,601%
Net Profit -231 -231
47% 47%
-1,539%

In millions USD.

Don't miss a Thing! We will send you all news about Centessa Pharmaceuticals plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Centessa Pharmaceuticals plc - ADR Stock News

Neutral
GlobeNewsWire
about 2 hours ago
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY.
Neutral
GlobeNewsWire
22 days ago
Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
Neutral
GlobeNewsWire
2 months ago
Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa. The milestones were achieved as Centessa initiated clinical development of ORX142, its second novel orexin receptor 2 (OX2R) agonist,...
More Centessa Pharmaceuticals plc - ADR News

Company Profile

Centessa Pharmaceuticals Ltd. operates as pharmaceutical company that develops medicines. The company was founded on October 26, 2020 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Saurabh Saha
Employees 98
Founded 2013
Website www.centessa.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today